Biswajit Kar is a Cardiology physician affiliated with Memorial Hermann–Texas Medical Center. OpenAlex indexes 111 publications with 2,486 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6400 Fannin St Ste 2500
Houston, TX 770301537
Telephone
713-704-4300Provider last certified this registry record 10 May 2022.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20252 payments
- Abbott LaboratoriesProgram year20255 payments
- Imperative Care, IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
68.5%Statin12.5%Atorvastatin Calcium58%Rosuvastatin Calcium32%Pravastatin Sodium8%Simvastatin3%Part D<11 patientsBeta blocker12%Metoprolol Succinate55%Carvedilol37%Metoprolol Tartrate6%Sotalol3%Part D<11 patients+ 15 more classes in this area
Metabolism & gastrointestinal
15.4%SGLT2 inhibitor8.6%Jardiance67%Farxiga29%Synjardy4%Part D<11 patientsPotassium supplement3.3%Potassium Chloride88%Klor-Con M2012%Part D<11 patients+ 4 more classes in this area
Blood & clotting
11.9%Factor Xa inhibitor5.5%Eliquis79%Xarelto21%Part D≥55 patientsP2Y12 inhibitor4%Clopidogrel91%Brilinta9%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2011 per NIH RePORTER. The latest:
- Combined Stem Cell and Assist Device Therapy for Heart Failure
Texas Heart Institute
FY2011$749,253P20HL101438 - Combined Stem Cell and Assist Device Therapy for Heart Failure
Texas Heart Institute
FY2010$741,860P20HL101438
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Kruskal Wallis and mRMR Feature Selection based Online Signature Verification System using Multiple SVM and KNN
International Journal of experimental research and review
2024 - Catastrophic Cardiac Events During Transcatheter Aortic Valve Replacement
Canadian Journal of Cardiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”